https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 The risk of secondary progressive multiple sclerosis is geographically determined but modifiable https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54611 Wed 06 Mar 2024 10:38:32 AEDT ]]> Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45667 Wed 02 Nov 2022 15:59:08 AEDT ]]> Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51272 Tue 29 Aug 2023 15:42:42 AEST ]]> Delay from treatment start to full effect of immunotherapies for multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39111 Tue 21 Mar 2023 17:45:24 AEDT ]]> Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49895 Tue 13 Jun 2023 15:49:48 AEST ]]> Comparative effectiveness in multiple sclerosis: A methodological comparison https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51624 Tue 12 Sep 2023 14:37:58 AEST ]]> Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53990 Thu 25 Jan 2024 13:04:15 AEDT ]]> Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52249 Thu 05 Oct 2023 14:07:20 AEDT ]]> Confirmed disability progression as a marker of permanent disability in multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52212 88% likely to be sustained (events with score ˃1.5). Conclusions: Clinicodemographic characteristics of 6-month confirmed disability progression events identify those at high risk of sustained long-term disability. This knowledge will allow future trials to better assess the effect of therapy on long-term disability accrual.]]> Thu 05 Oct 2023 10:22:58 AEDT ]]> Determinants of therapeutic lag in multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49695 Mon 29 May 2023 12:46:42 AEST ]]> Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50986 Mon 14 Aug 2023 15:59:28 AEST ]]> Disability accrual in primary and secondary progressive multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51685 Fri 15 Sep 2023 09:36:29 AEST ]]> Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51340 Fri 01 Sep 2023 13:35:50 AEST ]]>